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Nanoparticle contrast agents oﬀer the potential to significantly improve existing methods of cancer diagnosis and treatment.
Advantages include biocompatibility, selective accumulation in tumor cells, and reduced toxicity. Considerable research is
underway into the use of nanoparticles as enhancement agents for radiation therapy and photodynamic therapy, where they
may be used to deliver treatment agents, produce localized enhancements in radiation dose and selectively target tumor cells for
localized damage. This paper reviews the current status of nanoparticles for cancer treatment and presents preliminary results of a
pilot study investigating titanium dioxide nanoparticles for dual-mode enhancement of computed tomography (CT) imaging and
kilovoltage radiation therapy. Although titanium dioxide produced noticeable image contrast enhancement in the CT scans, more
sensitive detectors are needed to determine whether the nanoparticles can also produce localized dose enhancement for targeted
radiation therapy.
1. Introduction
Contrast agents are now standard practice in the field of
medical imaging, where they are used to enhance image
contrast and improve the visibility of features that would
otherwise be diﬃcult to detect [1]. Nanoparticle agents
continue to receive considerable attention in this field
for their potential as contrast agents [2], oﬀering the
advantage of greater biocompatibility and reduced toxicity
compared to more conventional chemical agents [3]. Present
nanoparticles under development for this role include gold
nanoparticles for X-ray contrast enhancement [3], magnetic
nanoparticles for MRI enhancement [4], and even hybrid
nanoparticles containing iron oxide and gold in a polymer
coating, which serve as contrast agents for both CT and MRI
[5].
In addition to imaging, nanoparticle agents are also
being investigated for potential applications to cancer therapy
[6–8], where they oﬀer similar advantages over other con-
trast agents as they do in imaging, coupled with the potential
for designing nanoparticles that can selectively accumulate
in cancer cells, providing “targeted” treatments that may
not be possible with conventional techniques [7]. Indeed,
nanoparticles have proven their use as a general platform
for targeted drug delivery, owing to the ability for tethered
functionality such as an antibody agent or quantum dot
fluorescent reporter to enhance delivery of chemotherapeutic
agents [9] (Figure 1). There is now also growing interest in
the use of nanoparticles as enhancement agents in cancer
radiation therapy and photodynamic therapy to improve
patient outcomes and reduce side eﬀects. As an increasing
number of cancer patients are treated with radiotherapy,
there is potential for a much wider impact of nanoparticle-
enhanced radiotherapy.
In this paper, we review the current status of nanoparticle
enhancement agents for radiation therapy and photody-
namic therapy. In addition, we present preliminary results
for a pilot study investigating the use of titanium dioxide
nanoparticles as possible dual-mode enhancement agents for
computed tomography (CT) imaging and radiation therapy.
2. Contrast-Enhanced Radiation Therapy
with Nanoparticles
There has been considerable investigation into the potential
of traditional imaging contrast agents, such as iodine, for
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Figure 1: Schematic of an iron-based nanoparticle showing multi-
functionality for image contrast and targeted drug delivery. (With
kind permission from A. L. Yuen, School of Chemistry, University
of Sydney.)
applications to radiation therapy cancer treatment [10–13].
During radiation therapy, ionising radiation is delivered to
the tumor, causing damage to the tumor cells’ DNA and
other biological molecules, resulting in the death of the
cell. Experiments on mice bearing Ehrlich ascites carcinoma
treated with iodine contrast agents have shown complete
regression in up to 80% of mice tested [10].
An inherent limitation of radiation therapy is the
unavoidable radiation dose delivered to healthy tissue sur-
rounding the tumor being treated. For some tumors, this
has limited the use of radiotherapy as the necessary dose to
destroy the tumor will also cause unacceptable damage to
nearby healthy tissue [14]. Contrast-enhanced radiotherapy
(CERT) [6] involves the administration of high-Z (i.e., high
atomic number) contrast agents to the target volume and
irradiation with kilovoltage X-rays. As high-Z materials have
diﬀerent absorption properties from surrounding tissue,
their presence can modify the distribution in absorbed dose;
in particular, a localized dose enhancement can be obtained
in regions where the contrast agent is present without
aﬀecting healthy tissue [11, 12]. As this diﬀerence in photo-
absorption properties is most pronounced at kilovoltage
energies [6, 15], kilovoltage X-rays are generally considered
to be the optimum energy range for CERT [12], but several
studies have also investigated contrast enhancement using
X-rays in the megavoltage energy range produced by medical
linear accelerators [16, 17].
In recent years, studies into potential radiotherapy
contrast agents have often focused on gold nanoparticles
[16–21]. Gold nanoparticles have a number of useful proper-
ties that make them highly attractive contrast agents for can-
cer therapy, particularly their high-Z and biocompatibility
[21, 22]. Monte Carlo simulations of interactions between
the radiation treatment beam and individual nanoparticles
indicate that the presence of a gold nanoparticle can increase
secondary electron production from a 50 kV X-ray beam by
up to a factor of 2000 compared to a similar volume of
water [23] (Figure 2). Nanoparticles smaller than 100 nm
can also cross human cell membranes and preferentially
accumulate in cancer cells [24]. Recent studies have found
that gold nanoparticles in conjunction with kilovoltage
radiotherapy can increase the one-year survival rate of mice
Figure 2: Monte Carlo visualization of the interaction of a low-
energy photon (green lines) with a 20 nm gold nanoparticle (yellow
sphere), showing electron tracks (red) associated with ionization
events. Solid and dashed lines correspond to events outside and
inside the nanoparticle, respectively. (Reprinted by permission from
Macmillan Publishers Ltd: Scientific Reports [22], copyright 2011.)
with EMT-6 mammary tumors to 86%, compared to 20%
with radiotherapy alone [19].
It has been observed that gold nanoparticles appear
to cause clinically relevant increases in cell killing rates
at concentrations well below those predicted by Monte
Carlo simulations [22, 25]. Although the simulations predict
that cell killing eﬀects should become noticeable only at
nanoparticle concentrations on the order of 1%, they have
been observed at concentrations orders of lower magnitude
[22]. It has been speculated that this discrepancy is due to
the Monte Carlo averaging of the eﬀects of the nanoparti-
cles over macroscopic volumes, thereby ignoring nanoscale
inheterogeneities in dose distribution in the vicinity of each
nanoparticle [22, 23]. Simulating these inheterogeneities and
their corresponding biological eﬀects predicts cell killing
at concentrations closer to those reported in experimental
studies [22].
An additional factor that is relevant to the eﬀects of
nanoparticles on cell killing is their radiosensitization prop-
erties. There is increasing evidence that gold nanoparticles,
while biocompatible, are not necessarily biologically inert
[25], which influences their eﬀects on cells during cancer
therapy. Gold nanoparticles have also demonstrated the
capacity to form radiosensitized DNAmolecules in cells they
aﬀect, making them more susceptible to radiation whilst
simultaneously increasing localised dose near the target [21].
One consequence of these biological eﬀects is that gold
nanoparticles appear to demonstrate considerably greater
cell killing eﬀects in some cell lines as compared to others
[25], which should be taken into consideration in future
studies.
3. Nanoparticles in Photodynamic
Cancer Therapy
Photodynamic therapy (PDT) is a treatment modality
which involves administering a photosensitive agent and
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illuminating the target area to activate the agent [26, 27].
In cancer therapy, existing PDT agents react upon pho-
tostimulation to produce cytotoxic oxygen species, killing
the target cell [27, 28]. Some of the advantages of PDT
include its localized eﬀects, reduced cost, and the fact that
it is largely an outpatient therapy [27]. Interestingly, it can
also induce immune responses even against tumors that
are not particularly immunogenic [7]. One of its primary
limitations, however, is the limited penetration depth of
visible, infrared, and UV radiation into the patient [27–29]
and the lack of eﬀective dosimetry techniques for PDT,
making it diﬃcult for dose distributions in the treatment
volume to be accurately measured [30].
As of 2010, only three classes of photosensitisers for PDT
had entered clinical use for cancer therapy [28, 30], all of
them chemical products rather than nanoparticles. However,
a myriad of nanoparticle PDT agents are presented in various
stages of development and show promise against a wide
range of cancers. These nanoparticles can be separated into
“passive” nanoparticles, which carry photosensitive agents,
and “active” particles, which are themselves involved in the
photostimulation process [7].
3.1. Passive Nanoparticles. A wide range of materials are
in use for passive nanoparticles, including gold [31], poly-
acrylamide [32], silica [33], and biodegradable polymers
[7]. One of their primary advantages over unencapsulated
photosensitizers is their ability to preferentially accumulate
in target cells [7, 33], which is of particular use given that
most photosensitizers described so far in the literature have
a low solubility in water and tend to accumulate in blood
cells rather than tumors. This allows similar therapeutic
eﬀects to be achieved with lower doses of conventional
photosensitizers such as hypericin, limiting their side eﬀects
[34]. Encapsulating potentially toxic photosensitizers inside
nanoparticles is another possibility, enabling their use in
patients when this might not otherwise be possible [7].
One issue that must be considered in passive photodynamic
nanoparticles is the optimum drug concentration within
the nanoparticle to achieve maximum therapeutic eﬀect, as
excessive drug loading can reduce the overall eﬀect of the
nanoparticles [34].
There is increasing presence in the literature of
biodegradable passive nanoparticles for photodynamic ther-
apy, typically made from polylactic acid or poly(lactic-co-
glycolic acid) [7]. These nanoparticles can selectively deliver
photosensitizers to target cells and then break down inside
the cell, releasing the photosensitizer into target cells. This
approach has seen impressive results in mouse models; in
a study involving the administration of the photosensitizer
hexadecafluoro zinc phthalocyanine to EMT-6 mammary
tumors in mice, encapsulation of the photosensitizer in
polylactic acid nanoparticles resulted in 100% of tested mice
achieving tumor regression, compared with only 60% of
mice administered the free drug [35]. Nanoparticle encapsu-
lation of Indocyanine green, recently evaluated as a possible
photosensitizer, was observed to increase organ deposition to
the photosensitizer to levels 2–8 times that for the free drug
[36]. Other photosensitizers which have observed beneficial
results from encapsulation in biodegradable nanoparti-
cles include hypericin [34] and zinc (II) phthalocyanine
[37].
3.2. Active Nanoparticles. A rare example of nanoparticles
that can act as a photosensitizer on their own are titanium
dioxide (TiO2) nanoparticles, which are receiving consider-
able attention as TiO2 is a known photocatalyst and reacts
with water to produce oxidizing free radicals when exposed
to UV light [38], which can result in localized damage to
nearby cells [38–40]. Recent in vitro studies on glioma cells
have demonstrated the potential of such nanoparticles for
photodynamic therapy [39]. A similar eﬀect has recently
been produced in TiO2 nanoparticles with ultrasonic stimu-
lation, which is able to kill nanoparticle-impregnated glioma
cells when exposed to ultrasound in a similar manner to UV-
stimulated nanoparticles [29]. TiO2 nanoparticles are also
essentially non toxic [41–43] and hence show considerable
promise as cancer therapy agents. Other nanoparticles that
have recently been shown to demonstrate photosensitizer
eﬀects include porous silicon and carbon-60 buckyballs
[8, 44].
Other active nanoparticles generally serve to enhance the
photodynamic process and are still used in conjunction with
a photosensitizer. The aim of these nanoparticles is usually
to generate light at frequencies useful for photodynamic
therapy in regions deeper inside the patient, sidestepping the
issue of the limited penetration hampering photodynamic
therapy at non superficial depths. The majority of studies
in this area has focused on “upconverting” nanoparticles,
which convert low-frequency near infrared radiation (NIR)
into frequencies usable for existing photosensitizers [7]. As
well as penetrating further into the patient, NIR is also less
damaging to the patient.
The most popular upconverting material for such
nanoparticles at present is sodium yttrium fluoride doped
with erbium and yttrium ions with a poly(ethylene imine)
coat, forming PEI/NaYF4: Yb3+, Er3+ nanoparticles [7, 27].
Proof-of-concept studies in rats have confirmed that these
upconverting nanoparticles can activate zinc phthalocyanine
photosensitisers in rats, with resultant therapeutic eﬀects,
upon stimulation with NIR radiation well outside the
absorption spectrum of the photosensitizer [27]. Upconvert-
ing nanoparticles, their photosensitizer, and a biocompatible
layer may be combined into “composite nanoparticles,”
which can produce millimolar quantities of cytotoxic rad-
icals upon illumination with NIR [45]. The upconverting
phosophor used in these nanoparticles may also be activated
with X-ray radiation, which would completely eliminate the
depth limitations of photodynamic therapy, at the expense of
increased healthy tissue damage [45].
4. Nanoparticles for Dual-Mode Imaging
and Therapy?
One area that remains relatively unexplored is the concept of
agents for dual-mode image contrast and therapy enhance-
ment. The concept of dual-mode enhancement agents has
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been tested using traditional non-nanoparticle image con-
trast agents, such as iodine, for radiotherapy enhancement
applications [11–13]. As iodine is routinely used as an image
contrast agent for CT scans [46], a conventional CT scanner
could in principle be used to simultaneously monitor tumor
progression and iodine uptake.
For nanoparticle-based enhancement agents, progress
remains limited, although initial studies combining MRI
enhancement and photodynamic therapy have recently
appeared in the literature [47, 48]. If nanoparticles for
radiotherapy using ionizing radiation were developed, how-
ever, it would be desirable to detect them on CT scanners
instead. CT scanners are the standard imaging technique
for diagnosis and treatment planning in virtually all can-
cer centres [49] and are increasingly replacing traditional
simulator units for radiotherapy treatment planning. It is
even possible to modify a conventional CT scanner to deliver
therapeutic X-ray doses using iodine CERT [12, 50]. This
treatment modality produces dose distributions similar to
those obtained with 10MV megavoltage therapy [12] and
enables combined imaging, simulation, and treatment with
the same machine. A similar option for more sophisticated
contrast agents such as TiO2 would be highly desirable and
deserves investigation.
4.1. A Pilot Study with TiO2 Nanoparticles. We conducted a
pilot study investigating the potential of TiO2 nanoparticles
as a potential contrast agent for dual-mode imaging and
therapy. We measured the eﬀects of each of these agents
on dose delivered by a kilovoltage X-ray therapy unit and
imaged nanoparticle-impregnated volumes with a clinical
CT scanner to determine their image contrast properties.
4.1.1. Methodology. In this study, rutile phase TiO2 nanopar-
ticles, with a diameter of 2-3 nm, were used. The concen-
tration of these solutions ranged from 0 to 0.231 g/mL.
The nanoparticles were fabricated using a DC magnetron-
assisted sputtering deposition system. Ultra-high-purity
argon and oxygen (both of purity greater than 99.99%) were
used as the sputtering and reactive gases, respectively. The
deposition process was carried out on ultrasonically cleaned
silicon wafers.
To evaluate their imaging capabilities, the nanoparticle
solutions were placed in a cylindrical plastic vial at a depth
of 1.5 cm. These vials were imaged using a Toshiba Aquilion
wide-bore CT scanner. The CT numbers of each vial in
Hounsfield Units (the standard units used in CT scans [45])
of each vial were plotted against concentration and a linear
fit was produced.
To evaluate their dose enhancement capabilities, the solu-
tions were irradiated on a Pantak Therapax DXT 300 kVp
X-ray unit. The solutions were placed in plastic containers
on the surface of an RMI solid-water phantom, such that
the nanoparticle solution had a thickness of 0.5 cm. Pieces
of radiation-sensitive EBT2 radiochromic film were placed
on the surface of the solution, such that the active layer was
facing the radiation source. The filmwas then irradiated with
a dose of 1.00Gy at the surface. The dose recorded by each
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Figure 3: CT numbers of titanium dioxide nanoparticle solutions
as a function of concentration (symbols, with error bars) and a
linear best fit.
film piece was plotted against nanoparticle concentration to
determine if the presence of the nanoparticles produced a
dose enhancement. The dose values were normalized with
respect to the dose recorded for the solution containing no
nanoparticles.
4.1.2. Results. The CT numbers of the scanned nanoparticle
concentrations are shown in Figure 3. A sample scan is
shown in Figure 4. The CT numbers of the nanoparticle
solutions increase approximately linearly with nanoparticle
concentration, ranging from 0± 5HU (no nanoparticles) to
281.5 ± 4HU (0.231 g/mL). The uncertainty in each mea-
surement (given by the standard deviation of the Hounsfield
unit measurements) is within 5HU for each measurement. A
nanoparticle concentration of 0.015 g/mL gives a reading of
26.6 ± 4 HU, which is greater than the typical noise value
of about 5HU reported on most CT scanners [46]. These
results indicate that even at low concentrations, the presence
of TiO2 nanoparticles produces detectable changes in the
CT numbers of scanned media which are detectable on a
conventional medical CT scanner.
The surface doses recorded by the EBT2 film pieces
as a function of nanoparticle concentration are shown in
Figures 5 and 6. For both energies, no enhancement eﬀects in
surface dose are observed. In both cases, the dose measured
in the solution containing no nanoparticles is the highest
measured. The dose measured at 50 kVp decays approxi-
mately monotonically with nanoparticle concentration. For
the 125 kVp beam energy, the fluctuations observed in the
dose measurements for all nanoparticle concentrations are
within the 4% calculated uncertainty. None of these values
are more than 97% of the dose measured for the vial
containing no nanoparticles. It is possible that the reduction
in surface dose at higher nanoparticle concentrations is due
to absorption of backscattered radiation near the surface
by the nanoparticle solutions, with no corresponding dose
enhancement to compensate for this. As such, it can be
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Figure 4: Sample coronal CT scan of a nanoparticle-containing
vial. The nanoparticle solution (of high attenuation) appears as
white, whereas the plastic frame containing the vial (of low
attenuation) appears black.
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Figure 5: Normalized surface dose recorded for the 50 kVp
radiation beam as a function of nanoparticle concentration.
concluded that a therapeutic enhancement in surface dose
is not observable using TiO2 nanoparticles of the phase
and concentrations investigated in this study, to within the
sensitivity limits of the film dosimetry technique that was
used.
5. Conclusion
Nanoparticles oﬀer enormous potential for improving can-
cer imaging and treatment. With demonstrated success in
existing diagnostic imaging and drug delivery techniques,
there is now growing interest in the potential applications
to radiation therapy and photodynamic therapy. Several
classes of nanoparticles are presently under development for
both of these techniques and are likely to enable significant
improvements to the eﬃcacy of existing cancer therapy
regimes in the foreseeable future. We reviewed the current
status of nanoparticle agents for cancer therapy. Preliminary
results for titanium dioxide nanoparticles as potential dual-
mode imaging and therapy enhancement agents indicate
they are a promising candidate for image contrast in com-
puted tomography. However, more comprehensive studies
are needed, with more sensitive detection techniques, to
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Figure 6: Normalized surface dose recorded for the 125 kVp
radiation beam as a function of nanoparticle concentration.
determine whether they may also serve to enhance radiation
dose for targeted cancer radiotherapy applications.
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